Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04204499

Analysis of Screen-detected Lung Cancers' Genomic Traits

Prospective, observational cohort study of patients undergoing surgical resection for low dose CT (LDCT) screen-detected lung cancer (detected through the SUMMIT study- ClinicalTrials.gov Identifier: NCT03934866/ lung screening programmes), in which translational research is a fundamental aspect.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

50 year–77 year

Sex eligibility

All sexes

Study type

Observational

Primary location

St Bart's Hospital, London, United Kingdom

Loading trial locations.

About this study

The ASCENT study seeks to examine the genomic signatures of screen-detected cancers, in order to categorise the biological behaviour of such lesions and correlate this against non-invasive biological and radiological parameters. From these data, the plan is to explore strategies to characterise LDCT-detected cancers through non-invasive means, which the researchers believe may prove key in mitigating potential screening-associated harms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with confirmed lung cancer or probable lung cancer via LDCT screening.
  • Planned for, or completed primary surgical resection either for histologically confirmed lung cancer, or strongly suspected lung cancer.
  • Able to provide written informed consent (or verbal informed consent for participants consenting to retrospective diagnostic samples and data collection only).

Exclusion criteria

  • Treatment with neoadjuvant therapy for current lung malignancy as per local MDT treatment decision.
  • Known Active Human Immunodeficiency Virus (HIV), Hepatitis B virus, Hepatitis C Virus or Syphilis.

Treatment and study plan

Primary outcomes

  1. Genomic exploratory research

    Time frame: 4 years

    Measuring the differences in chromosomal instability between fast- and slow-growing screen detected cancers, quantified by weighted genome integrity index (WGII) derived from whole exome sequencing (WES) data

Sponsors and collaborators

Lead sponsor

University College, London

Other

Registry information

Acronym: ASCENT

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Dec 19, 2019
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.